Study Shows Combination Therapy Leads to Better Outcomes for Newly Diagnosed T2D Patients

The new study shows combination therapy in patients newly diagnosed with Type 2 diabetes provides better outcomes than metformin alone.

FDA Approves First Ready-to-Use Liquid Stable Glucagon Gvoke

On September 10 the FDA approved the Gvoke HypoPen and Gvoke PFS, emergency glucagon rescue devices for the treatment of severe hypoglycemia.

ADA 2019 – American Diabetes Association’s 79th Annual Conference

The Beyond Type 2 team's live coverage of the American Diabetes Association's 79th Annual Conference.

Half-Price Generics of NovoLog and NovoLog Mix Announced by Novo Nordisk

Novo Nordisk announced that authorized generic versions of NovoLog and NovoLog Mix will be made available on January 2, 2020.

Nasal Glucagon Baqsimi Approved by the FDA

On Thursday, the Food and Drug Administration approved Eli Lilly and Company's Baqsimi, a non-injectable, nasal glucagon and the first of its kind.

Non-Insulin Drug Approved for Kids with T2D by FDA

Victoza, a liraglutide injection, was approved by the U.S. Food and Drug Administration. It's the first non-insulin drug approved for pediatric use in nearly 20 years.

Colorado Becomes First State to Pass Bill Capping Insulin Costs

On Wednesday, May 22, Colorado became the first state in the U.S. to put a price cap on insulin.

Express Scripts Won’t Cover Lilly’s Generic Insulin

The largest PBM in the U.S. recently released a list of formulary exclusions that included 'Insulin Lispro' as an excluded medication.

Previously Healthy from Beyond Type 1 Named Webby People’s Voice Award Winner

Hailed as the “Internet’s highest honor” and “the Oscars of the Internet” The Webby Awards are presented by the International Academy of Digital Arts and Sciences (IADAS) honoring excellence on the Internet.

Insulin Manufacturers and PBMs Testify Before Congress

The hearing was contentious throughout, with House members grilling both the manufacturers and the PBM representatives about the reasons for high costs.